A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "The Drug Delivery Road Gets Tougher," features profiles of ActoGeniX, Atacama Labs, Glide Pharma and Mimetic Solutions. Plus these Start-Ups Across Health Care: Light Dimensions, Relyspa, Stentys and Thrombotargets.
You may also be interested in...
The design of currently marketed stents is not optimal in treating stenosis in or next to coronary bifurcations. Stentys, founded by noted cardiologist and entrepreneur Jacques Séguin, MD, PhD, aims to improve on outcomes while keeping things simple. It believes its bifurcation stent will be as easy for cardiologists to use as conventional stents, but that its novel design will provide superior clinical results by enabling full opening and scaffolding of the side branch.
Might a $200 handheld skin rejuvenation device for home use and sold primarily through a 30-minute infomercial be the key to riches for investors? Light Dimensions' founders and backers hope so. A 2005 entrant into the booming home-use aesthetic device market, Light Dimensions has launched its first product, the LED-based RejuvaWand for minimizing visible signs of aging.
When Amgen bought Ilypsa last summer, it kept one of its non-absorbed polymer drug candidates for itself, leaving Ilypsa's other candidates in limbo. Key Ilypsa employees and investors wanted to carry out those programs, and with Amgen's blessing, they moved swiftly to form Relypsa Inc., which retains rights to Ilypsa's remaining pipeline and drug discovery platform. Relypsa management, all from Ilypsa, intends to continue Ilypsa's fast pace of pipeline development, with a NCE planned for entry into the clinic every year for the next three years.